Rolf Panel Rolf
•Download as PPT, PDF•
0 likes•148 views
I
IDSConference on Health and Social Protection: Meeting the needs of the poor, 9-10 October 2008 www.povill.com
Report
Share
Report
Share
Recommended
Embedding family drug and alcohol courts (FDAC's) within English family justi...
This document discusses the findings of an evaluation of the Family Drug and Alcohol Court (FDAC) program in the UK. The evaluation compared outcomes for 90 families involved in FDAC to 101 comparison families in ordinary family courts. Key findings include:
- A higher proportion of parents in FDAC stopped misusing substances compared to the comparison group. 40% of FDAC mothers and 25% of FDAC fathers stopped misusing versus 25% and 5% respectively in the comparison group.
- FDAC had better family reunification outcomes, with 35% of FDAC mothers both stopping substance misuse and being reunited with their children, compared to 19% in the comparison group.
- Further episodes of neglect or abuse were
Stakeholder Mapping of a Doctor
The document outlines various common and unique partners in healthcare governance. Common partners that work together include patients, doctors, hospitals, clinics, pharmacies, staff, and service providers like laboratories and therapists. Unique partners with separate roles are government organizations, non-profits, educational groups, medical associations, insurance companies, and pharmaceutical/device companies who all play distinct parts in the overall healthcare system.
Week 2 2012 suggested answers_week 1
This document discusses the positive and negative aspects of pharmaceutical companies and ways their ethical behavior can be assessed. Positively, they help build healthcare infrastructure in poor countries and research new drugs and remedies. Negatively, they are accused of overpricing, patenting traditional medicines, not researching diseases in developing nations, and misrepresenting trial results. Their ethics can be assessed using rankings like the Covalence Ethical Rankings or the Access to Medicine Index, though these rely partly on self-reporting.
Genetic Testing Reduces Specialty Drug Spend
An award-winning WellDyneRx study, recognized by the Academy of Managed Care Pharmacy, found that pharmacogenomics screening saved self-funded employers 5 percent in specialty drug claim costs.
Clinical Trials
This document discusses clinical trials, including their definition as a systematic approach to study a drug or process to determine if it works, the types of trials, regulations like good clinical practice that govern them, how they are designed with objectives, populations, and statistical analyses, how randomization and blinding are used, who can sponsor them, their phases from preclinical to post-marketing, and terms like investigational new drugs and new drug applications. It emphasizes that clinical trials follow strict ethics rules and regulations to ensure safety, efficacy, and quality.
Trigger Point – Self-medication: Patients in white coats
This document summarizes the key points from a presentation on self-medication given at the Pharmacon 2007 European Congress. The presentation covered:
- The structure of the pharmaceutical market and definitions of prescription vs non-prescription medicines
- Results from a study on consumer attitudes towards purchasing self-medication products at pharmacies across Europe
- Areas of cooperation between industry groups representing manufacturers of non-prescription medicines and pharmacist/medical doctor organizations
- The economic and public health value of self-medication
- The future role of pharmacists in supporting self-care and recommendations around pharmacy design, education, and visibility of non-prescription products.
The Orphan Drug Act
The document summarizes the Orphan Drug Act of 1983 and its impact. It provides incentives like 7 years of marketing exclusivity and tax credits to stimulate development of drugs for rare diseases defined as affecting fewer than 200,000 people. Since 1983, over 1000 designations and 200 product approvals have occurred. While the Act has met its objectives, concerns around the high costs of orphan drugs and determining appropriate access and reimbursement are discussed.
Risk and Benefit Walk Together
This document discusses safety concerns regarding the class of antibiotics known as fluoroquinolones. It notes that while common side effects were established when these drugs were approved decades ago, more serious side effects affecting mental health and blood sugar levels have been recognized more recently based on expanded data. The document expresses concern that fluoroquinolone use is irrationally high in Pakistan compared to other countries, and serious side effects are underreported. It argues this indicates weaknesses in Pakistan's regulatory system that prioritize economic interests over patient safety. Recent actions by the FDA to strengthen fluoroquinolone labels are also summarized.
Recommended
Embedding family drug and alcohol courts (FDAC's) within English family justi...
This document discusses the findings of an evaluation of the Family Drug and Alcohol Court (FDAC) program in the UK. The evaluation compared outcomes for 90 families involved in FDAC to 101 comparison families in ordinary family courts. Key findings include:
- A higher proportion of parents in FDAC stopped misusing substances compared to the comparison group. 40% of FDAC mothers and 25% of FDAC fathers stopped misusing versus 25% and 5% respectively in the comparison group.
- FDAC had better family reunification outcomes, with 35% of FDAC mothers both stopping substance misuse and being reunited with their children, compared to 19% in the comparison group.
- Further episodes of neglect or abuse were
Stakeholder Mapping of a Doctor
The document outlines various common and unique partners in healthcare governance. Common partners that work together include patients, doctors, hospitals, clinics, pharmacies, staff, and service providers like laboratories and therapists. Unique partners with separate roles are government organizations, non-profits, educational groups, medical associations, insurance companies, and pharmaceutical/device companies who all play distinct parts in the overall healthcare system.
Week 2 2012 suggested answers_week 1
This document discusses the positive and negative aspects of pharmaceutical companies and ways their ethical behavior can be assessed. Positively, they help build healthcare infrastructure in poor countries and research new drugs and remedies. Negatively, they are accused of overpricing, patenting traditional medicines, not researching diseases in developing nations, and misrepresenting trial results. Their ethics can be assessed using rankings like the Covalence Ethical Rankings or the Access to Medicine Index, though these rely partly on self-reporting.
Genetic Testing Reduces Specialty Drug Spend
An award-winning WellDyneRx study, recognized by the Academy of Managed Care Pharmacy, found that pharmacogenomics screening saved self-funded employers 5 percent in specialty drug claim costs.
Clinical Trials
This document discusses clinical trials, including their definition as a systematic approach to study a drug or process to determine if it works, the types of trials, regulations like good clinical practice that govern them, how they are designed with objectives, populations, and statistical analyses, how randomization and blinding are used, who can sponsor them, their phases from preclinical to post-marketing, and terms like investigational new drugs and new drug applications. It emphasizes that clinical trials follow strict ethics rules and regulations to ensure safety, efficacy, and quality.
Trigger Point – Self-medication: Patients in white coats
This document summarizes the key points from a presentation on self-medication given at the Pharmacon 2007 European Congress. The presentation covered:
- The structure of the pharmaceutical market and definitions of prescription vs non-prescription medicines
- Results from a study on consumer attitudes towards purchasing self-medication products at pharmacies across Europe
- Areas of cooperation between industry groups representing manufacturers of non-prescription medicines and pharmacist/medical doctor organizations
- The economic and public health value of self-medication
- The future role of pharmacists in supporting self-care and recommendations around pharmacy design, education, and visibility of non-prescription products.
The Orphan Drug Act
The document summarizes the Orphan Drug Act of 1983 and its impact. It provides incentives like 7 years of marketing exclusivity and tax credits to stimulate development of drugs for rare diseases defined as affecting fewer than 200,000 people. Since 1983, over 1000 designations and 200 product approvals have occurred. While the Act has met its objectives, concerns around the high costs of orphan drugs and determining appropriate access and reimbursement are discussed.
Risk and Benefit Walk Together
This document discusses safety concerns regarding the class of antibiotics known as fluoroquinolones. It notes that while common side effects were established when these drugs were approved decades ago, more serious side effects affecting mental health and blood sugar levels have been recognized more recently based on expanded data. The document expresses concern that fluoroquinolone use is irrationally high in Pakistan compared to other countries, and serious side effects are underreported. It argues this indicates weaknesses in Pakistan's regulatory system that prioritize economic interests over patient safety. Recent actions by the FDA to strengthen fluoroquinolone labels are also summarized.
Final Poster PDF NAEMSP 2016
This study compared pediatric drug dosages in 38 EMS protocols to those listed on the Broselow Length-Based Tape. The researchers found significant discrepancies, with 49% of medications listed at incongruent doses on the tape and 38% of medications missing from the tape altogether. The most commonly missing medications were ondansetron, diphenhydramine, morphine, and albuterol. The medications most often listed at incorrect doses were epinephrine IM, midazolam, fentanyl, and diazepam. The study concluded that a significant discrepancy exists between pediatric drug dosages in EMS protocols and those on the Broselow tape.
Patient involvement
This document discusses patient involvement at the Medicines Evaluation Board (MEB) in the Netherlands. It makes three key points:
1. The MEB focuses on involving patients throughout the entire life cycle of a medicinal product to ensure the patient perspective is considered. Meetings are held 3-4 times per year and minutes are published online.
2. Strategies for patient involvement at the MEB include having a board member represent the patient perspective, consulting patient organizations on regulatory decisions and guidelines, and creating an online portal for patients.
3. Eliciting individual patient preferences could help identify subgroups with similar preferences to better tailor regulatory decisions and highlight situations where regulator and patient values differ requiring improved communication.
Drugs for rare diseases, Orphan Drugs
This document discusses drugs for rare diseases. It begins by defining rare diseases according to different organizations. Rare diseases are individually rare but collectively common, affecting around 6-8% of the global population. Developing drugs for rare diseases is challenging due to the small patient populations and high costs. Governments provide incentives like tax breaks and exclusive rights to encourage pharmaceutical companies to develop orphan drugs. Recent advances in genetics have helped identify causes of many rare diseases and accelerated drug development. While treatment options have increased in recent decades, more understanding and viable treatments are still needed for most rare diseases.
Prescription Drugs Part 1 Trends
This document summarizes trends and motives for prescription drug abuse among college students. It finds that 16.2 million Americans aged 12 and older reported non-medical use of prescription drugs in the past year, including 6% of those aged 18-25. Among high schoolers, 4% reported non-medical use of prescriptions in the past month. College students have high rates as well, with 17% reporting lifetime non-medical use and 10.6% of college men and 6.8% of college women reporting past-year opioid use. Common motives for abuse include beliefs that prescription drugs are safer than street drugs and not addictive. The document provides resources for additional information on prescription drug abuse.
Rolf Panel Ross Degnan
Conference on Health and Social Protection: Meeting the needs of the poor, 9-10 October 2008
www.povill.com
Successful New Drug Development Strategies for Small Companies
This document provides advice for small biotech companies on successful new drug development. It emphasizes that new drug development is a risky process, with many potential pitfalls that can cause drugs to fail. Some key recommendations include understanding the strengths and weaknesses of the drug, learning from previous similar drugs, rigorously selecting preclinical and clinical doses, focusing on efficacy biomarkers with potential, and considering partnerships if drug delivery technology could help. The document stresses that drug development is a marathon, not a sprint, and one should not oversell the science until it is proven.
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...
1) Pfizer conducted an unauthorized clinical trial in Nigeria during a meningitis outbreak, testing an experimental antibiotic on children without proper consent. At least 11 children died and many developed health issues.
2) Clinical trials are increasingly being conducted in developing countries due to lower costs, less regulation, and easier access to patient populations. However, this raises ethical issues around informed consent and vulnerable populations.
3) The Helsinki Declaration provides ethical guidelines for human trials, including informed consent, prioritizing subject well-being over science, and post-trial access to proven therapies. However, following all guidelines can be difficult in developing country contexts.
Orphan drugs
orphan diseases, Indian scenario of Orphan disease management, Drugs for Orphan diseases. Orphan drug act
Validity of meternal recall of prescription drug use during pregnancy
Validity and reliability of maternal recall of prescription drug use during pregnancy
By Marian Bakker
Why Pharmaceutical Prices are Rising and How We Can Fight Against Them?
Pharmaceutical prices are rising due to minimal government regulation, lack of competition, end of generic drugs wave, supply disruptions and industry consolidation. This leads to increased healthcare costs, formulary changes, nonadherence and rationing of medications. Possible solutions include increasing price transparency, competition, importing drugs from other countries, and legislation prohibiting pay-for-delay deals. Harris Health implemented cost control strategies like a closed formulary, therapeutic substitutions, and patient assistance programs, achieving over $60 million in savings and cost avoidance in fiscal year 2016.
UTSpeaks: A medicated nation (Part 1: Prof Shalom Benrimoj)
Medications are both the cheapest form of treatment but also contribute to health risks, with at least 2-4% of hospital admissions being drug-related and over 30% for those over age 75. As the population ages and chronic diseases increase, polypharmacy and non-compliance pose issues to addressing health effectively through medications. Pharmacists can play an important role in medication management through services like MedsChecks, Home Medication Reviews, and improving appropriate use and compliance to reduce costs and health risks.
DEVENDER Pv
This document discusses the importance of pharmacovigilance in improving patient safety and promoting rational medicine use. It outlines the World Health Organization's role in establishing global standards and supporting national pharmacovigilance programs. The key goals of pharmacovigilance are to detect unknown or rare adverse drug reactions, understand intrinsic and extrinsic risk factors, and prevent future harm through education and clinical training.
SHARING VISION – TOWARDS BIOMEDICINE PARTNERS
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
Epidemiology of Substance Use Disorders
Victor Maestre Ramirez completed an educational activity on Understanding Addiction held by Harvard Medical School on June 18, 2018. The activity was approved for 1 CME credit by the AAPA Review Panel and was planned in accordance with AAPA standards for enduring material programs. The program focused on the epidemiology of substance use disorders.
Education - Do we have a choice?
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
Specialty one pager FINAL
This document discusses specialty drug management solutions from PwC. It notes that specialty drugs are the fastest growing component of pharmacy costs, accounting for 32% of costs while only representing 1% of prescriptions. There are concerns about the high and increasing costs of specialty drugs, variations in their management across pharmacy and medical benefits, and lack of transparency. PwC's approach involves diagnosing spending trends, formulating management strategies like innovative pricing and site of care optimization, and implementing programs to realize annual savings of 5-15% or $186,000-$558,000 for a typical employer.
Goran Panel Bounfeng
The document discusses bridging the gap between research, policy, and practice in Laos. It outlines the current structure which involves research institutions conducting studies that are then disseminated to line ministries and the Ministry of Health to inform policy. However, there are still hindering factors such as limitations in research activities, insufficient funding, and a shortage of local researchers. Efforts are being made to improve utilizing evidence in policymaking, such as through health research forums and an evidence-informed policy network, but challenges remain in strengthening the use of research in Laos.
Bringing Sexuality And Rights Out In The Open Building A Platform In Bangladesh
This presentation was delivered by the James P Grant School of Public Health to a workshop at the Liverpool School of Tropical Medicine on improving the use of research in policy and practice.
Engaging Mass Media in Communicating SRH Research in sub-Saharan Africa
This presentation was delivered by the African Population and Health Center to a workshop at the Liverpool School of Tropical Medicine on improving the use of research in policy and practice.
Women’s sexual and reproductive health – increasing the evidence base
The document discusses women's sexual and reproductive health issues in sub-Saharan Africa. It outlines high maternal mortality rates, low modern contraceptive use, high HIV prevalence disproportionately affecting women, and high rates of unsafe abortion and gender-based violence in the region. It also notes data and methodological challenges in studying these issues and proposes responses like integrating reproductive health services, prioritizing adolescents and unsafe abortion, and increasing domestic resource mobilization.
More Related Content
What's hot
Final Poster PDF NAEMSP 2016
This study compared pediatric drug dosages in 38 EMS protocols to those listed on the Broselow Length-Based Tape. The researchers found significant discrepancies, with 49% of medications listed at incongruent doses on the tape and 38% of medications missing from the tape altogether. The most commonly missing medications were ondansetron, diphenhydramine, morphine, and albuterol. The medications most often listed at incorrect doses were epinephrine IM, midazolam, fentanyl, and diazepam. The study concluded that a significant discrepancy exists between pediatric drug dosages in EMS protocols and those on the Broselow tape.
Patient involvement
This document discusses patient involvement at the Medicines Evaluation Board (MEB) in the Netherlands. It makes three key points:
1. The MEB focuses on involving patients throughout the entire life cycle of a medicinal product to ensure the patient perspective is considered. Meetings are held 3-4 times per year and minutes are published online.
2. Strategies for patient involvement at the MEB include having a board member represent the patient perspective, consulting patient organizations on regulatory decisions and guidelines, and creating an online portal for patients.
3. Eliciting individual patient preferences could help identify subgroups with similar preferences to better tailor regulatory decisions and highlight situations where regulator and patient values differ requiring improved communication.
Drugs for rare diseases, Orphan Drugs
This document discusses drugs for rare diseases. It begins by defining rare diseases according to different organizations. Rare diseases are individually rare but collectively common, affecting around 6-8% of the global population. Developing drugs for rare diseases is challenging due to the small patient populations and high costs. Governments provide incentives like tax breaks and exclusive rights to encourage pharmaceutical companies to develop orphan drugs. Recent advances in genetics have helped identify causes of many rare diseases and accelerated drug development. While treatment options have increased in recent decades, more understanding and viable treatments are still needed for most rare diseases.
Prescription Drugs Part 1 Trends
This document summarizes trends and motives for prescription drug abuse among college students. It finds that 16.2 million Americans aged 12 and older reported non-medical use of prescription drugs in the past year, including 6% of those aged 18-25. Among high schoolers, 4% reported non-medical use of prescriptions in the past month. College students have high rates as well, with 17% reporting lifetime non-medical use and 10.6% of college men and 6.8% of college women reporting past-year opioid use. Common motives for abuse include beliefs that prescription drugs are safer than street drugs and not addictive. The document provides resources for additional information on prescription drug abuse.
Rolf Panel Ross Degnan
Conference on Health and Social Protection: Meeting the needs of the poor, 9-10 October 2008
www.povill.com
Successful New Drug Development Strategies for Small Companies
This document provides advice for small biotech companies on successful new drug development. It emphasizes that new drug development is a risky process, with many potential pitfalls that can cause drugs to fail. Some key recommendations include understanding the strengths and weaknesses of the drug, learning from previous similar drugs, rigorously selecting preclinical and clinical doses, focusing on efficacy biomarkers with potential, and considering partnerships if drug delivery technology could help. The document stresses that drug development is a marathon, not a sprint, and one should not oversell the science until it is proven.
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...
1) Pfizer conducted an unauthorized clinical trial in Nigeria during a meningitis outbreak, testing an experimental antibiotic on children without proper consent. At least 11 children died and many developed health issues.
2) Clinical trials are increasingly being conducted in developing countries due to lower costs, less regulation, and easier access to patient populations. However, this raises ethical issues around informed consent and vulnerable populations.
3) The Helsinki Declaration provides ethical guidelines for human trials, including informed consent, prioritizing subject well-being over science, and post-trial access to proven therapies. However, following all guidelines can be difficult in developing country contexts.
Orphan drugs
orphan diseases, Indian scenario of Orphan disease management, Drugs for Orphan diseases. Orphan drug act
Validity of meternal recall of prescription drug use during pregnancy
Validity and reliability of maternal recall of prescription drug use during pregnancy
By Marian Bakker
Why Pharmaceutical Prices are Rising and How We Can Fight Against Them?
Pharmaceutical prices are rising due to minimal government regulation, lack of competition, end of generic drugs wave, supply disruptions and industry consolidation. This leads to increased healthcare costs, formulary changes, nonadherence and rationing of medications. Possible solutions include increasing price transparency, competition, importing drugs from other countries, and legislation prohibiting pay-for-delay deals. Harris Health implemented cost control strategies like a closed formulary, therapeutic substitutions, and patient assistance programs, achieving over $60 million in savings and cost avoidance in fiscal year 2016.
UTSpeaks: A medicated nation (Part 1: Prof Shalom Benrimoj)
Medications are both the cheapest form of treatment but also contribute to health risks, with at least 2-4% of hospital admissions being drug-related and over 30% for those over age 75. As the population ages and chronic diseases increase, polypharmacy and non-compliance pose issues to addressing health effectively through medications. Pharmacists can play an important role in medication management through services like MedsChecks, Home Medication Reviews, and improving appropriate use and compliance to reduce costs and health risks.
DEVENDER Pv
This document discusses the importance of pharmacovigilance in improving patient safety and promoting rational medicine use. It outlines the World Health Organization's role in establishing global standards and supporting national pharmacovigilance programs. The key goals of pharmacovigilance are to detect unknown or rare adverse drug reactions, understand intrinsic and extrinsic risk factors, and prevent future harm through education and clinical training.
SHARING VISION – TOWARDS BIOMEDICINE PARTNERS
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
Epidemiology of Substance Use Disorders
Victor Maestre Ramirez completed an educational activity on Understanding Addiction held by Harvard Medical School on June 18, 2018. The activity was approved for 1 CME credit by the AAPA Review Panel and was planned in accordance with AAPA standards for enduring material programs. The program focused on the epidemiology of substance use disorders.
Education - Do we have a choice?
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
Specialty one pager FINAL
This document discusses specialty drug management solutions from PwC. It notes that specialty drugs are the fastest growing component of pharmacy costs, accounting for 32% of costs while only representing 1% of prescriptions. There are concerns about the high and increasing costs of specialty drugs, variations in their management across pharmacy and medical benefits, and lack of transparency. PwC's approach involves diagnosing spending trends, formulating management strategies like innovative pricing and site of care optimization, and implementing programs to realize annual savings of 5-15% or $186,000-$558,000 for a typical employer.
What's hot (16)
Successful New Drug Development Strategies for Small Companies
Successful New Drug Development Strategies for Small Companies
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...
Validity of meternal recall of prescription drug use during pregnancy
Validity of meternal recall of prescription drug use during pregnancy
Why Pharmaceutical Prices are Rising and How We Can Fight Against Them?
Why Pharmaceutical Prices are Rising and How We Can Fight Against Them?
UTSpeaks: A medicated nation (Part 1: Prof Shalom Benrimoj)
UTSpeaks: A medicated nation (Part 1: Prof Shalom Benrimoj)
Viewers also liked
Goran Panel Bounfeng
The document discusses bridging the gap between research, policy, and practice in Laos. It outlines the current structure which involves research institutions conducting studies that are then disseminated to line ministries and the Ministry of Health to inform policy. However, there are still hindering factors such as limitations in research activities, insufficient funding, and a shortage of local researchers. Efforts are being made to improve utilizing evidence in policymaking, such as through health research forums and an evidence-informed policy network, but challenges remain in strengthening the use of research in Laos.
Bringing Sexuality And Rights Out In The Open Building A Platform In Bangladesh
This presentation was delivered by the James P Grant School of Public Health to a workshop at the Liverpool School of Tropical Medicine on improving the use of research in policy and practice.
Engaging Mass Media in Communicating SRH Research in sub-Saharan Africa
This presentation was delivered by the African Population and Health Center to a workshop at the Liverpool School of Tropical Medicine on improving the use of research in policy and practice.
Women’s sexual and reproductive health – increasing the evidence base
The document discusses women's sexual and reproductive health issues in sub-Saharan Africa. It outlines high maternal mortality rates, low modern contraceptive use, high HIV prevalence disproportionately affecting women, and high rates of unsafe abortion and gender-based violence in the region. It also notes data and methodological challenges in studying these issues and proposes responses like integrating reproductive health services, prioritizing adolescents and unsafe abortion, and increasing domestic resource mobilization.
Brief Introduction to POVILL
This document outlines a study to understand how major illnesses impact rural households in Asian transitional economies and evaluate strategies to help households cope with related economic consequences. The study aims to inform policies protecting the poor by examining the effects of different illnesses, household coping strategies, performance of support schemes, provider costs, and influences on policy formulation. The research is a collaboration between institutions in the UK, China, Cambodia, Lao PDR, Belgium, and Sweden.
Viewers also liked (7)
Bringing Sexuality And Rights Out In The Open Building A Platform In Bangladesh
Bringing Sexuality And Rights Out In The Open Building A Platform In Bangladesh
Engaging Mass Media in Communicating SRH Research in sub-Saharan Africa
Engaging Mass Media in Communicating SRH Research in sub-Saharan Africa
Women’s sexual and reproductive health – increasing the evidence base
Women’s sexual and reproductive health – increasing the evidence base
More from IDS
Building Institutions for an effective health system
This presentation was given by Gerald Bloom at the Global Symposium on Health Systems Research, November, 2010.
Analysis of cross-country changes in health services
This presentation was given in a session at the Global Symposium on Health Systems Research which was organised by the Future Health Systems Consortium. The author is Toru Matsubayashi from Johns Hopkins Bloomberg School of Public Health
The scale and scope of private contributions to health systems
This presentation was given at a session at the Global Symposium on Health Systems Research in November 2010. Panelists included Ruth Berg, Gerry Bloom, Birger Forsberg, Kara Hanson, Gina Lagomarsino, Dominic Montagu, Stefan Nachuk
Presentation on the literature review of interventions to improve health care...
This presentation was given in a Future Health System Consortium organised session at the Global Symposium on Health Systems Research in November 2010. The author is Alex Rowe from the Centers for Disease Control and Prevention.
Evidence on Improving Health Service Delivery in Developing Countries
This presentation by David Peters of the Future Health Systems Consortium was given at the Global Symposium on Health Systems Research in November 2010.
Pathways to Scaling up Health Services in Complex Adaptive Systems
This presentation by Ligia Paina & David Peters was given as part of a Future Health System Consortium session at the Global Symposium on Health Systems Research. It is part of our Beyond Scaling Up stream of work.
The Parliamentarians’ Perception of the Public Health Sector in Afghanistan
This document summarizes a survey of Afghan parliamentarians on their perceptions of the public health sector. Key findings include:
- Most parliamentarians agreed that the quality and amount of health services have improved but disagreed that people are happy with services or know what the Ministry is doing.
- Top health problems were seen as child health, maternal health, and mental health.
- Resources should focus on both rural and urban areas.
- User fees should not be implemented in clinics or hospitals.
- The health sector budget should be increased from 10% actual to 19% recommended.
Lessons Learned from Case Studies on Effective Service Delivery
This presentation by Katja Janovsky was given in a Future Health Systems Consortium session at the Global Symposium on Health System Research.
Learning by Doing and Applying our Learning
This presentation was given by Sara Bennett in a Future Health Systems Consortium session at the Global Symposium on Health System Research.
Institutional Analysis of the Ministry of Public Health at Central and Provin...
The document summarizes the findings of an institutional analysis of the Ministry of Public Health in Afghanistan at the central and provincial levels. It identifies strengths and challenges in key stewardship functions like setting strategies, developing technical guidelines, coordination, budgeting, monitoring and evaluation. It provides recommendations to address gaps in policies, guidelines, capacity and resources to help the Ministry strengthen its stewardship role over the health sector.
Implementing Rapid Medical Security reform in China: Importance of a Learning...
A presentation by Zhenzhong ZHANG and Yunping WANG of the China National Health Development Research Center. This was given at a Future Health Systems Consortium organised event at the Global Symposium on Health System Research.
From research to policy CNHDRC strategies
This presentation was given by Zhenzhong ZHANG and Yunping WANG of the China National Health Development Research Center at the Global Symposium on Health System Research.
Evaluation of health systems performance: the role of Health Systems Research
This presentation was given by Sara Bennett of the Future Health Systems Consortium at the Global Symposium on Health Systems Research.
Making the right to health a reality to Indigenous People in Brazil
The document summarizes Brazil's efforts to provide universal healthcare coverage, particularly for indigenous peoples, through its public health system (SUS). It discusses how the SUS expanded coverage from 1.1 million people in 1994 to 96.1 million in 2009, and reduced infant mortality rates from 47.1 to 19.3 per 1000 births from 1990 to 2007. It also notes indigenous peoples still face health inequities, with infant mortality rates of 22.9 for whites, 34.9 for blacks, and 51.14 for indigenous peoples. The document outlines Brazil's creation of an Indigenous Health Subsystem in 1999 to decentralize services and improve quality and access for indigenous communities, but notes challenges remain around uneven health gains and centralization.
Afghanistan Health Sector Balanced Scorecard
This presentation was given at the Global Symposium on Health System Research in November 2010. The authors are L P Singh, Olakunle Alonge, Anubhav Agarwal,
Kayhan Natiq, S D Gupta and David Peters.
What must be done? Capacity building for health systems research in low & mid...
This presentation was given in plenary by Sara Bennett of the Future Health Systems Consortium at the Global Symposium on Health Systems Research, November 2010.
What must be done to ehance capacity for health systems research?
This presentation was written by Sara Bennett, Ligia Paina, Christine Kim, Irene Agyepong, Somsak Chunharas, Di McIntyre and Stefan Nachuk for the Global Symposium on Health Systems Research, November, 2010.
IMPROVING HEALTH SERVICE DELIVERY IN DEVELOPING COUNTRIES: FROM EVIDENCE TO ...
This presentation was given by David Peters, Sameh El-Saharty, Banafsheh Siadat, Katja Janovsky, and Marko Vujicic at the Global Symposium on Health Systems Research, November 2010.
Pathways to scaling up health services Peters and Paina
This document discusses scaling up health services in complex adaptive systems. It argues that health systems behave like complex adaptive systems, characterized by heterogeneous actors that interact in dynamic and unpredictable ways. Scaling up is therefore not a linear or controlled process. The document outlines several concepts from complexity science that are relevant to scaling up, such as feedback loops, emergent behavior, tipping points, and path dependence. It suggests using theories and methods from complexity science to better understand scaling up and facilitate decision making. Key lessons are that scaling up requires flexibility, recognizing local conditions, and developing sustainable institutions over the long term through learning-based approaches.
Beyond technical solutions PRINN in Nigeria
The document summarizes a program in Northern Nigeria aimed at improving health outcomes through strengthening governance and service delivery. It discusses the political and historical context, outlines the program's goals and theories of change, describes early successes like establishing an integrated local health system board, and concludes that achieving health system reform requires addressing both technical and political factors through multifaceted engagement strategies tailored to the local context.
More from IDS (20)
Building Institutions for an effective health system
Building Institutions for an effective health system
Analysis of cross-country changes in health services
Analysis of cross-country changes in health services
The scale and scope of private contributions to health systems
The scale and scope of private contributions to health systems
Presentation on the literature review of interventions to improve health care...
Presentation on the literature review of interventions to improve health care...
Evidence on Improving Health Service Delivery in Developing Countries
Evidence on Improving Health Service Delivery in Developing Countries
Pathways to Scaling up Health Services in Complex Adaptive Systems
Pathways to Scaling up Health Services in Complex Adaptive Systems
The Parliamentarians’ Perception of the Public Health Sector in Afghanistan
The Parliamentarians’ Perception of the Public Health Sector in Afghanistan
Lessons Learned from Case Studies on Effective Service Delivery
Lessons Learned from Case Studies on Effective Service Delivery
Institutional Analysis of the Ministry of Public Health at Central and Provin...
Institutional Analysis of the Ministry of Public Health at Central and Provin...
Implementing Rapid Medical Security reform in China: Importance of a Learning...
Implementing Rapid Medical Security reform in China: Importance of a Learning...
Evaluation of health systems performance: the role of Health Systems Research
Evaluation of health systems performance: the role of Health Systems Research
Making the right to health a reality to Indigenous People in Brazil
Making the right to health a reality to Indigenous People in Brazil
What must be done? Capacity building for health systems research in low & mid...
What must be done? Capacity building for health systems research in low & mid...
What must be done to ehance capacity for health systems research?
What must be done to ehance capacity for health systems research?
IMPROVING HEALTH SERVICE DELIVERY IN DEVELOPING COUNTRIES: FROM EVIDENCE TO ...
IMPROVING HEALTH SERVICE DELIVERY IN DEVELOPING COUNTRIES: FROM EVIDENCE TO ...
Pathways to scaling up health services Peters and Paina
Pathways to scaling up health services Peters and Paina
Recently uploaded
Best Forex Brokers Comparison in INDIA 2024
Navigating the world of forex trading can be challenging, especially for beginners. To help you make an informed decision, we have comprehensively compared the best forex brokers in India for 2024. This article, reviewed by Top Forex Brokers Review, will cover featured award winners, the best forex brokers, featured offers, the best copy trading platforms, the best forex brokers for beginners, the best MetaTrader brokers, and recently updated reviews. We will focus on FP Markets, Black Bull, EightCap, IC Markets, and Octa.
Authentically Social by Corey Perlman - EO Puerto Rico
Authentically Social by Corey Perlman - EO Puerto RicoCorey Perlman, Social Media Speaker and Consultant
Social media for business The effects of customers service quality and online reviews on customer loyal...
The effects of customers service quality and online reviews on customer loyal...balatucanapplelovely
Research In the Adani-Hindenburg case, what is SEBI investigating.pptx
Adani SEBI investigation revealed that the latter had sought information from five foreign jurisdictions concerning the holdings of the firm’s foreign portfolio investors (FPIs) in relation to the alleged violations of the MPS Regulations. Nevertheless, the economic interest of the twelve FPIs based in tax haven jurisdictions still needs to be determined. The Adani Group firms classed these FPIs as public shareholders. According to Hindenburg, FPIs were used to get around regulatory standards.
Company Valuation webinar series - Tuesday, 4 June 2024
This session provided an update as to the latest valuation data in the UK and then delved into a discussion on the upcoming election and the impacts on valuation. We finished, as always with a Q&A
-- June 2024 is National Volunteer Month --
Check out our June display of books on voluntary organisations
Hamster Kombat' Telegram Game Surpasses 100 Million Players—Token Release Sch...
Hamster Kombat' Telegram Game Surpasses 100 Million Players—Token Release Schedule Unveiled
Top mailing list providers in the USA.pptx
Discover the top mailing list providers in the USA, offering targeted lists, segmentation, and analytics to optimize your marketing campaigns and drive engagement.
Recruiting in the Digital Age: A Social Media Masterclass
In this masterclass, presented at the Global HR Summit on 5th June 2024, Luan Wise explored the essential features of social media platforms that support talent acquisition, including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok.
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka➒➌➎➏➑➐➋➑➐➐Dpboss Matka Guessing Satta Matka Kalyan Chart Indian Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka Indian satta Matka Dpboss Matka Kalyan Chart Matka Boss otg matka Guessing Satta Digital Transformation and IT Strategy Toolkit and Templates
This Digital Transformation and IT Strategy Toolkit was created by ex-McKinsey, Deloitte and BCG Management Consultants, after more than 5,000 hours of work. It is considered the world's best & most comprehensive Digital Transformation and IT Strategy Toolkit. It includes all the Frameworks, Best Practices & Templates required to successfully undertake the Digital Transformation of your organization and define a robust IT Strategy.
Editable Toolkit to help you reuse our content: 700 Powerpoint slides | 35 Excel sheets | 84 minutes of Video training
This PowerPoint presentation is only a small preview of our Toolkits. For more details, visit www.domontconsulting.com
Recently uploaded (20)
Authentically Social by Corey Perlman - EO Puerto Rico
Authentically Social by Corey Perlman - EO Puerto Rico
The effects of customers service quality and online reviews on customer loyal...
The effects of customers service quality and online reviews on customer loyal...
In the Adani-Hindenburg case, what is SEBI investigating.pptx
In the Adani-Hindenburg case, what is SEBI investigating.pptx
Company Valuation webinar series - Tuesday, 4 June 2024
Company Valuation webinar series - Tuesday, 4 June 2024
Hamster Kombat' Telegram Game Surpasses 100 Million Players—Token Release Sch...
Hamster Kombat' Telegram Game Surpasses 100 Million Players—Token Release Sch...
Recruiting in the Digital Age: A Social Media Masterclass
Recruiting in the Digital Age: A Social Media Masterclass
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka
The Influence of Marketing Strategy and Market Competition on Business Perfor...
The Influence of Marketing Strategy and Market Competition on Business Perfor...
Training my puppy and implementation in this story
Training my puppy and implementation in this story
Digital Transformation and IT Strategy Toolkit and Templates
Digital Transformation and IT Strategy Toolkit and Templates
The Influence of Marketing Strategy and Market Competition on Business Perfor...
The Influence of Marketing Strategy and Market Competition on Business Perfor...
The Influence of Marketing Strategy and Market Competition on Business Perfor...
The Influence of Marketing Strategy and Market Competition on Business Perfor...
Rolf Panel Rolf
- 1. Conference Health and social protection: Meeting the needs of the poor Vientiane 2008 Rolf Wahlström, Karolinska Institutet, Sweden Strategies for improving pharmaceutical use www.povill.com
- 6. Strategies for improving pharmaceutical use Dennis Ross-Degnan, Harvard University, USA Challenges and effects of insurance mechanisms Lamphone Syhakhang, MoH, Lao PDR Regulatory approaches in Laos Paul Newton, Wellcome Trust, UK Combating counterfeit drugs in Asia Case: Antibiotics in China Chenggang Jin, China; Adrian Ely, UK